Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable [clinical] result” cheered Wall Street, ...
NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology ... In the press release, Steve Harr, Sana's President and Chief ...
Shares of Sana Biotechnology surged after the company ... intramuscularly with no immunosuppression," Chief Executive Steve Harr said.
As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...
Sana Biotechnology has shared early data for ... in a fully immune competent individual,” Sana CEO and president Steve Harr, M.D., said in the release. “Safe cell transplantation without ...
Hosted on MSN16d
This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.Sana Biotechnology (SANA), a clinical-stage ... modified islet cells were able to evade immune system attacks. CEO Steve Harr stated, “As far as we are aware, this is the first study showing ...
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology ... will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback